Stuttering - Epidemiology Forecast - 2032

DelveInsight’s ‘Stuttering- Epidemiology Forecast–2032’ report delivers an in-depth understanding of the Stuttering, historical and forecasted epidemiology as well as the Stuttering trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Stuttering Disease Understanding

Childhood-onset fluency disorder, also known as stuttering or stammering, is a common multifactorial speech disorder. It is a disruption in the fluency of verbal expression characterized by involuntary, audible, or silent repetitions or prolongations of sounds or syllables. These are not readily controllable and may be accompanied by other movements and by emotions of negative nature such as fear, embarrassment, or irritation, and are normally seen with recurrent prolongations, reverberations, or blocks of sounds, syllables, phrases, or words.

As it is a disorder in the fluency of speech, in addition to involuntary repetition and prolongation of sounds and syllables, there is also “secondary stuttering behavior,” which occurs as a response to the core stuttering behavior. These can be further explained by the example of “flight behaviors”, varying from choosing synonyms for the feared words to opting for social isolation to avoid speaking and concealing the stuttering out of anxiety, frustration, and shame. There are also “fight behaviors” varying from unnatural eye-blinking to involuntary movement of the extremities.

Stuttering arises, in general, before age 6, usually between 2.5 and 4 years of age. The most common form of stuttering is referred to as developmental stuttering. This may be contrasted with other forms of stuttering, which, for instance, arise from a neurological condition, trauma or emotional stress. Clinical diagnosis typically measures the rates of stuttering dysfluencies while reading or during free speech and can include the rate of ancillary symptoms, sometimes known as struggle behaviors, during speech.

Stuttering Diagnosis

Stuttering is usually diagnosed by a speech-language pathologist (SLP), a health professional trained to test and treat individuals with voice, speech, and language disorders. The SLP will consider a variety of factors, including the following:
Child’s case history (such as when the stuttering was first noticed and under what circumstances)
An analysis of the child’s stuttering behaviors
An evaluation of the child’s speech and language abilities and the impact of stuttering on their life

When evaluating a young child for stuttering, a speech-language pathologist will try to determine if the child is likely to continue their stuttering behavior or outgrow it. To determine this difference, the SLP will consider such factors as the family’s history of stuttering, whether the child’s stuttering has lasted 6 months or longer, and whether the child exhibits other speech or language problems.

Some aspects of stuttering are apparent, while others are not. A speech-language pathologist (SLP) can make a comprehensive and reliable diagnosis. Stuttering is more than disfluencies, so it is important to see an SLP for testing.

Different guidelines and expert committees have designated different parameters for classification of Stuttering.

Continued in the report…..

Stuttering Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Stuttering, diagnosed prevalent cases of Stuttering and gender-specific diagnosed prevalent cases of Stuttering, scenario of Stuttering in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Stuttering Detailed Epidemiology Segmentation
Total prevalent cases of stuttering in the 7MM were found to be approximately 3,981,012 in 2021. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019–2032).
Among 7MM, the United States has the highest prevalent cases of stuttering with 1,636,434 cases in 2021.
The total diagnosed prevalent cases of stuttering in the 7MM were observed to be 878,024 in 2021. These cases are expected to increase during the study period (2019–2032).
A total of 409,108 diagnosed prevalent cases of stuttering were recorded in the US in 2021, these cases are expected to rise at a CAGR of 0.8% for the study period (2019–2032).
Among the European countries, Germany had the highest diagnosed prevalent population of Stuttering with 88,573 cases, followed by the UK with 67,196 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
In Japan, 132,528 diagnosed prevalent cases of stuttering were recorded in the year 2021.
As per DelveInsight’s assessment, for stuttering, the gender-specific distribution of the disease suggests male predominance with 658,518 cases while females were at a lower count with 219,506 cases in the 7MM.

Scope of the Report
The report covers the descriptive overview of stuttering, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report assesses the disease risk and burden of stuttering.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report provides the segmentation of the disease epidemiology for 7MM, prevalent cases of stuttering, diagnosed prevalent cases of stuttering and gender-specific diagnosed prevalent cases of stuttering.

Report Highlights
11-Year Forecast of Stuttering
The 7MM Coverage
Total prevalent cases of stuttering
Diagnosed prevalent cases of stuttering
Gender-specific diagnosed prevalent cases of stuttering

Key Questions Answered
What are the disease risk and burdens of stuttering?
What is the historical stuttering patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
What would be the forecasted patient pool of stuttering at the 7MM level?
What will be the growth opportunities across the 7MM concerning the patient population about stuttering?
Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of stuttering during the forecast period (2022–2032)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Reasons to buy

The stuttering report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the 7MM stuttering epidemiology forecast.
The stuttering epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
The stuttering epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019–2032